DUBLIN --(BUSINESS WIRE)--Jul. 28, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at
DUBLIN --(BUSINESS WIRE)--Jul. 14, 2026-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results. The webcast player and accompanying slides may be accessed
— First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2 — — Improvements in Patient-Reported Cognition and Fatigue Were Also Sustained —
— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Narcolepsy Type 2 — — Improvements in Wakefulness and Patient-Reported Cognition and
DUBLIN --(BUSINESS WIRE)--Jun. 15, 2026-- Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH),
— 26 Abstracts Accepted Demonstrate Alkermes’ Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia — — Detailed Positive Results from Vibrance-2 Phase 2 Study of Alixorexton, an Orexin 2 Receptor Agonist, in Patients With Narcolepsy Type 2 to be Shared in
DUBLIN --(BUSINESS WIRE)--Jun. 3, 2026-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47 th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET ( 3:00 p.m. BST).
— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — DUBLIN --(BUSINESS WIRE)--May 26, 2026-- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data
– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative